Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells.

Lee PH, Yamamoto TN, Gurusamy D, Sukumar M, Yu Z, Hu-Li J, Kawabe T, Gangaplara A, Kishton RJ, Henning AN, Vodnala SK, Germain RN, Paul WE, Restifo NP.

J Exp Med. 2019 Aug 12. pii: jem.20181218. doi: 10.1084/jem.20181218. [Epub ahead of print]

PMID:
31405895
2.

Mg2+ regulation of kinase signaling and immune function.

Kanellopoulou C, George AB, Masutani E, Cannons JL, Ravell JC, Yamamoto TN, Smelkinson MG, Jiang PD, Matsuda-Lennikov M, Reilley J, Handon R, Lee PH, Miller JR, Restifo NP, Zheng L, Schwartzberg PL, Young M, Lenardo MJ.

J Exp Med. 2019 Aug 5;216(8):1828-1842. doi: 10.1084/jem.20181970. Epub 2019 Jun 13.

PMID:
31196981
3.

T cell stemness and dysfunction in tumors are triggered by a common mechanism.

Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, Lee PH, Shin M, Patel SJ, Yu Z, Palmer DC, Kruhlak MJ, Liu X, Locasale JW, Huang J, Roychoudhuri R, Finkel T, Klebanoff CA, Restifo NP.

Science. 2019 Mar 29;363(6434). pii: eaau0135. doi: 10.1126/science.aau0135.

PMID:
30923193
4.

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA.

J Clin Invest. 2019 Feb 25;129(4):1551-1565. doi: 10.1172/JCI121491. eCollection 2019 Feb 25.

5.

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, Stroncek DF, Gattinoni L, Feldman SA, Restifo NP.

JCI Insight. 2017 Dec 7;2(23). pii: 95103. doi: 10.1172/jci.insight.95103.

6.

Identification of essential genes for cancer immunotherapy.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP.

Nature. 2017 Aug 31;548(7669):537-542. doi: 10.1038/nature23477. Epub 2017 Aug 7.

7.

Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction.

Cruz AC, Ramaswamy M, Ouyang C, Klebanoff CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R, Price S, Casellas R, Rao VK, Lippincott-Schwartz J, Restifo NP, Siegel RM.

Nat Commun. 2016 Dec 23;7:13895. doi: 10.1038/ncomms13895.

8.

Ionic immune suppression within the tumour microenvironment limits T cell effector function.

Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP.

Nature. 2016 Sep 22;537(7621):539-543. doi: 10.1038/nature19364. Epub 2016 Sep 14.

9.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP.

J Clin Invest. 2016 Jan;126(1):318-34. doi: 10.1172/JCI81217. Epub 2015 Dec 14.

10.

Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells.

Klebanoff CA, Yamamoto TN, Restifo NP.

Nat Rev Clin Oncol. 2014 Dec;11(12):685-6. doi: 10.1038/nrclinonc.2014.190. Epub 2014 Nov 11. No abstract available.

11.

Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.

McGoldrick SM, Bleakley ME, Guerrero A, Turtle CJ, Yamamoto TN, Pereira SE, Delaney CS, Riddell SR.

Blood. 2013 Apr 4;121(14):2796-803. doi: 10.1182/blood-2012-09-453720. Epub 2013 Feb 14.

12.

Novel serial positive enrichment technology enables clinical multiparameter cell sorting.

Stemberger C, Dreher S, Tschulik C, Piossek C, Bet J, Yamamoto TN, Schiemann M, Neuenhahn M, Martin K, Schlapschy M, Skerra A, Schmidt T, Edinger M, Riddell SR, Germeroth L, Busch DH.

PLoS One. 2012;7(4):e35798. doi: 10.1371/journal.pone.0035798. Epub 2012 Apr 24.

13.

Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine.

Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Dong L, Marshak JO, McClurkan CL, Yamamoto TN, Bailer SM, Laing KJ, Wald A, Verjans GM, Koelle DM.

J Clin Invest. 2012 Feb;122(2):654-73. doi: 10.1172/JCI60556. Epub 2012 Jan 3. Erratum in: J Clin Invest. 2012 Aug 1;122(8):3024.

14.

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.

Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR.

Blood. 2012 Jan 5;119(1):72-82. doi: 10.1182/blood-2011-07-366419. Epub 2011 Oct 26.

15.

Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.

Anderson LD Jr, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR.

Cancer Immunol Immunother. 2011 Jul;60(7):985-97. doi: 10.1007/s00262-011-1009-3. Epub 2011 Apr 3.

16.

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR.

Blood. 2010 Nov 25;116(22):4532-41. doi: 10.1182/blood-2010-05-283309. Epub 2010 Aug 11.

Supplemental Content

Loading ...
Support Center